U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07772882) titled 'Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer' on Aug. 14.
Brief Summary: This is an open-label, Phase 1 clinical study to evaluate the safety, tolerability, PK profiles, and clinical activity of IV and PO arginine supplementation + SOC chemoimmunotherapy regimens in participants with PROC.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Platinum Resistant Ovarian Cancer
Fallopian Tube Cancers
Peritoneal Carcinoma
Intervention:
DRUG: Cohort A1
Weekly paclitaxel + q3w pembrolizumab +/- bevacizumab + 4.5g daily oral arg...